Duchenne Muscular Dystrophy Market Size, Share, Growth Analysis, By Therapy(Mutation Suppression, Exon Skipping Approach, Others Therapies), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region - Industry Forecast 2024-2031

Duchenne Muscular Dystrophy Market Driver

• Prevalence of duchenne muscular dystrophy is on the rise, and factors that are driving its market growth include increased awareness campaigns about the disorder, the development of mutation-specific therapies, the rise in product pipelines, the introduction of therapies like Exondys51 and Translarna, and the use of corticosteroid-based anti-inflammatory drugs.
• Other factors driving the growth of the duchenne muscular dystrophy market include the population's potential for rising healthcare costs in developed nations and the accessibility of medical reimbursement in various locations. The long-standing unmet need for the treatment of muscular dystrophy illnesses represents the primary growth opportunity for a number of market competitors. Numerous businesses are now conducting clinical studies to prepare new medications for DMD treatment.

Duchenne Muscular Dystrophy Market Restraint

• Global duchenne muscular dystrophy market is anticipated to see significant challenges due to late diagnosis of DMD and decreased seeking rate as a result of prognosis. The fact that different outcome measures are needed at various stages of the disease and that these measures frequently lack sensitivity and objectivity makes it difficult to track how well DMD medications are working right now. For example, the 6 minute walk test, the most used outcome measure in DMD clinical trials, can only be used on ambulant DMD patients (5 years of age) and requires a sizable cohort and a lengthy period of time after treatment to detect a meaningful benefit. A lack of valid outcome measures for these particular age ranges also frequently results in the exclusion of very young children (4 years of age) and non-ambulant patients (12 years of age) from clinical trials. The market for treatments for Duchenne muscular dystrophy is growing as a result of the aforementioned claims.